Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Instituto De Investigación Sanitaria Incliva is currently prosecuting patent applications in the Biotechnology & Pharmaceuticals technology area. The portfolio features 1 pending office action, suggesting a focused stage of examination for its biotech or pharmaceutical innovations. This single action indicates that the institute is currently prioritizing a specific technological advancement within the Biotechnology & Pharmaceuticals field.
The prosecution process is streamlined through 1 distinct examiner and 1 distinct art unit. Having 1 distinct examiner means that the institute's legal representatives are interacting with a single individual at the USPTO, which can lead to a more consistent and predictable dialogue. The 1 distinct art unit involved further narrows the technical scope of the examination, ensuring that the 1 pending office action is reviewed by a specialized group.
EMCH, GREGORY S is the busiest examiner for the institute, with 1 busiest examiner pending office action currently under review. This 1 action is the only pending matter in the portfolio, making EMCH, GREGORY S the primary figure in the institute's current patent office interactions. Success for this portfolio depends on effectively addressing the specific feedback provided by EMCH, GREGORY S in this 1 busiest examiner pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EMCH, GREGORY S | 1 | 48.5% | +43.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18548043 | METHODS FOR THE MEASUREMENT OF PROTEIN C AND ACTIVATED PROTEIN C | EMCH, GREGORY S | 31d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18548043 | METHODS FOR THE MEASUREMENT OF PROTEIN C AND ACTIVATED PROTEIN C | EMCH, GREGORY S | 31d overdue |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18548043 | METHODS FOR THE MEASUREMENT OF PROTEIN C AND ACTIVATED PROTEIN C | EMCH, GREGORY S | 1678 | §101§103§112 | Non-Final OA | 31d overdue | Pending | Aug 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial